turnaround start
upgrad outperform concern solosec ramp-up margin
contract play view stock market ignor
sharp increas year two strong product
opportun genbrel europ gspiriva inhal us upgrad
outperform under-perform increas target price
increas lupin turn net debt posit
past four year due weak acquisit gavi solosec low
higher wc intens margin contract due solosec price eros
metformin howev lupin could close debt-fre
margin bottom improv driven ramp-up
levothyroxin solosec albuterol inhal launch
genbrel gspiriva alreadi moder
capital-expenditure intens
multipl catalyst expect genbrel approv
eu albuterol inhal launch possibl goa facil clearanc
high amortis solosec depress profit
solosec expect lupin either reduc sale rep ramp-up stay weak
add anoth brand product share solosec resourc target
price base price-to-earnings ep ex-amortis
npv genbrel gspiriva view spiriva upsid
factor limit competit larg opportun
approv issu like gadvair cut ep
factor new tax rate guidanc higher
yet factor upsid cost control initi
risk approv delay genbrel albuterol inhal pend
inspect indor dabhasa api plant potenti escal
oai flag mandideep gavi facil disrupt generic-gener
scale-up india introduc ep
valuat metric
chg prev ep
rate under-perform outperform
number share mn
price month
price rel chart measur perform
 bse sensex close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau pm univers toronto focu chart tabl
figur significantli improv lupin onward
ramp
sharp wc
figur gspiriva upsid per share expect launch us
gener
figur genbrel upsid per share expect launch eu
gener
figur ep bridg lupin
figur sotp cs tp lupin
charl martineau pm univers toronto lupin sole filer
gspiriva
competit genbrel
limit
sub mn
factor
upsid cost
control guidanc
turnaround start
spiriva enbrel could upsid
ignor market
view stock market ignor upsid genbrel eu
upsid npv gspiriva us tp limit competit
larg opportun spiriva inhal bn drug global lupin file
dpi form spiriva handihal sh bn us sale lupin
gener filer clinic trial on-going us sh market
contract ellipta inhal gsk gain volum share boehring
shift handihal market respimat devic mdi conveni use
base case assum market reduc mn lower
litig key patent composit patent expir juli take
genbrel market eu larg bn sandoz
lupin alreadi approv japan expect eu approv
competit limit follow-on filer coheru prioritis us file eu
lupin upsid come manufactur margin profit share deduct
partner share privat equiti share fund part enbrel
develop cost expect volum share thu
repres real upsid enbrel henc valu drug npv basi
solosec drag reduc lower resourc
product
solosec significantli depress profit posit ramp-up
manag reduc expect mn mn still
expect sub mn expect lupin either reduc sale rep ramp-up
stay weak add anoth brand product share solosec resourc expect
solosec ebitda break-even ep break-even levo lupin
good start market share expect share
approv rld volum share increas lupin expand
capac function price eros levo may remain limit follow-on
gener compani come larg capac albuterol opportun
still good price eros high three authoris gener enter
market upsid lupin depend sequenc approv among cipla
lupin howev albuterol inhal remain limit competit opportun
expect upgrad
lupin turn net debt past four year due weak acquisit gavi solosec low
higher wc intens margin contract due solosec price eros
metformin howev lupin could close debt free margin
bottom improv driven ramp-up levothyroxin solosec
albuterol inhal genbrel gspiriva lupin alreadi
moder capital-expenditure intens tp base price-to-earnings ep
ex amortis npv genbrel gspiriva view spiriva
upsid factor limit competit larg opportun
approv issu like gadvair cut ep
factor new tax rate guidanc higher yet factor upsid
cost control initi risk approv delay genbrel
albuterol inhal pend inspect indor dabhasa api plant potenti
escal oai flag mandideep gavi facil disrupt generic-
gener scale-up india
lupin limit india-bas pharmaceut compani
compani develop market rang gener formul
activ pharmaceut ingredi api market around
world focus chronic therapi lifestyl segment
price jun rate under-perform outperform target price
good sold
profit tax
free cash flow firm
net chang cash
multipl ep ad back rs ep account
acquisition-rel amort also assign upsid rs
npv gspiriva launch expect rs npv
biosimilar enbrel launch partner eu expect
delay resolut warn letter goa indor plant
plant receiv oai flag price eros
us increas doubl digit lupin wit
earn cut de-rat grey scenario base lower
ep project rs vs base case estim rs
assign multipl scenario factor
upsid gspiriva genbrel
price rel chart measur perform bse sensex
close
spot exchang rate
spiriva enbrel could rs
upsid ignor market
view stock market ignor upsid genbrel eu
upsid npv gspiriva tp limit competit larg
opportun spiriva inhal bn drug global lupin file dpi
form spiriva handihal sh bn sale us lupin
gener filer clinic trial on-going us sh market
contract ellipta inhal gsk gain volum share boehring
shift handihal market respimat devic mdi conveni use
base case assum market reduc mn lower till
litig key patent composit patent expir juli take
genbrel market eu larg bn sandoz
lupin alreadi approv japan expect eu approv
competit limit follow-on filer coheru prioritis us file eu lupin
upsid come manufactur margin profit share deduct partner
share privat equiti share fund part enbrel develop cost
expect volum share thu
repres real upsid enbrel therefor valu drug npv basi
spiriva larg product bn global sale boehring ingelheim
bi use mainten treatment asthma chronic obstruct
pulmonari diseas copd spiriva present two form dpi form spiriva
handihal launch may approv copd mdi form spiriva
respimat launch approv asthma copd lupin file
dpi form far lupin gener filer spiriva handihal
remain limit competit opportun given activ clinic trial
done prove bioequival spiriva handihal
spiriva dpi declin brand still present larg opportun
bn drug us current
im level spiriva handihal bn drug us wherea respimat
size bn spiriva handihal trx consist declin year
overal spiriva franchis handihal respimat suffer due increas
competit gsk ellipta inhal seri launch onward four inhal
launch one anoro ellipta prove improv efficaci spiriva
handihal consciou effort bi shift spiriva handihal market spiriva
respimat possibl anticip eventu gener competit handihal
mdi product easier-to-breath form conveni use respimat
aerosol cartridg last month wherea handihal capsul need replac
dose therefor continu gain market share handihal
overal basi spiriva franchis share inhal market declin
exit exit figur
lupin sole filer
gspiriva
competit genbrel
limit
spiriva avail two
form mdi dpi
lupin file dpi
larger variant
spiriva dpi
declin due
shift mdi
bn sale
us
charl martineau pm univers toronto figur spiriva franchis share declin wake intensifi competit gsk inhal
introduc part ellipta seri onward
within spiriva handihal share declin due continu shift
volum respimat sinc launch decemb figur
declin year sinc respimat launch figur reflect ims-level sale well
handihal share spiriva
figur denot exit share cy iqvia credit suiss research
base analysi prevail split handihal respimat
estim current sale spiriva handihal bn annualis
manufactur level sizabl
charl martineau pm univers toronto spiriva still larg
mn
expiri
expir
schedul
anticip bi get aggress shift volum respimat post lupin
anda file estim share loss year vs current run rate even
account rate cede share respimat handihal market size
expect larg excess mn manufactur level possibl time
lupin gener entri
lupin launch like
lupin file anda spiriva handihal may subsequ litig
bi august novemb infring six patent six
patent highlight key patent block lupin entri beyond
devic patent expir march howev lupin guid
abl prove non-infring devic patent thu launch post
patent expiri possibl
figur devic patent hold key determin lupin launch timelin
type
claim patent
main composit patent powder prepar tiotropium
excipi inhal process prepar
crystallin tiotropium certain chemic properti
composit api excipi method treatment
diseas claim drug formul
crystallin tiotropium certain chemic properti process
prepar api
pharmaceut composit api certain chemic properti
inhal kit method administ inhal powder
process produc powder prepar inhal
per current case timelin trial district court expect conclud
stay approv expir april
constrain factor lupin even account month timelin
possibl appeal expect court trial get patent
except devic patent get expir henc lupin obtain non-infring
rule devic patent expect launch sometim compani
mention analyst reason confid avoid infring devic
figur timelin on-going litig district court
lupin su bi
submiss consent discoveri confidenti order
expert discoveri relat claim construct
close fact discoveri
close expert discoveri
expir stay
risk delay
approv case
get list ob
lupin confirm
sole ftf litig
gener file far
orion
gener player
clinic trial
european market
risk delay launch aris due case timelin get
extend delay fda approv lupin gener bi list new
patent orang book protect product
point predict reason concern
surround point given fda took consider length time approv gadvair
dpi key reason delay batch-by-batch variat result
interact two api advair combin inhal two api
fluticason propion salmeterol xinafo worri lupin due
singl api present spiriva howev caus delay
predict moment
favour rule would offer lupin extend period gener
exclus littl competit
lupin confirm sole ftf litig spiriva
litig gener therefor lupin enjoy exclus
also reason chanc extend gener exclus market
consider period time case lupin obtain favour non-infring rule
abl launch sinc larg market month exclus
contribut meaning lupin sale
four activ dmf file besid lupin howev seem
potenti gener competitor lupin us given record past clinic trial
except one player orion pharma howev orion mention commun
develop tiotropium bromid inhal european market
also support fact clinic trial conduct finland
figur activ dmf file tiotropium bromid
spiriva add per share target price
estim lupin launch competit anticip market size
handihal mn almost half current size thereaft assum steadi
increment gener launch lead increas price eros loss market share
anoth assumpt calcul anticip shift market
handihal respimat expect minimis post genericis cost
benefit lower price altern handihal may like counter-bal
increment product benefit respimat valu upsid spiriva npv basi
figur spiriva npv
gener
month
lupin enbrel enter
larg market eu
bn two
enbrel europ strong opportun valu
lupin alreadi obtain approv enbrel biosimilar japan expect
approv european market lupin partner eu
nichi-iko japanes market two market opportun
significantli larger eu market market size bn biosimilar entri
sandoz launch eu market market size current
bn figur market first biosimilar biogen
one-third market sandoz market
figur enbrel market split europ
figur biosimilar progress enbrel market
europ
launch
reach share
assumpt expect partner launch reach market
share three year genbrel remain attract opportun medium term
follow-on competit limit coheru phase mylan/biocon
phase partner lupin also coheru prioriti higher us
market eu market coheru file return shire acquir baxalta
competit
activ player
coheru us-focus
figur enbrel biosimilar phase
enbrel upsid
larg captur
valu enbrel upsid
npv basi
enbrel upsid start larg part upsid captur
like take time take market share go exampl sandoz
taken two year reach market share margin profil enbrel
good given larg size product competit limit three biosimilar
target price includ enbrel npv basi equival
profit product valu drug npv basi expect
competit drug post lupin share profit market
margin privat equiti player fund part enbrel develop
addit lupin also make margin genbrel suppli lupin suppli genbrel
pune facil alreadi obtain cgmp clearanc
figur genbrel upsid lupin europ
gener
sub
solosec loss
reduc sale ramp
ebitda/ep break-
even
solosec drag reduc
resourc product
solosec significantli depress profit posit ramp-up
manag reduc expect mn mn still
expect sub mn expect lupin either reduc sale rep ramp-up
stay weak add anoth brand product share solosec resourc expect
solosec ebitda break-even ep break-even
levothyroxin lupin good start market share expect
share approv rld volum share increas
lupin expand capac function price eros levothyroxin
may remain limit follow-on gener compani come larg capac
albuterol opportun still good price eros high three
authoris gener enter market upsid lupin depend sequenc
approv among cipla lupin howev albuterol inhal remain
solosec significantli drag profit
alway cautiou solosec potenti given high price solosec
efficaci better conveni one dosag solosec vs twice day seven
day treatment metronidazol manag scale expect
mn mn still believ solosec stay mn
peak solosec list price post rebat cost insur compani
per dose co-pay patient high get reduc
lupin co-pay coupon therefor patient use lupin co-pay
coupon lupin get net price net realis medicar
even lower discount even higher get coverag
strategi lupin increas net realis solosec period time
reduc number subsidis coupon market howev initi ramp-up
slow lupin alreadi cut number medic rep
solosec significantli impact profit pbt lower
due solosec profit tax even lower solosec loss off-set
consolid profit solosec part us subsidiari loss make
overal us profit larger part profit captur india base transfer
price solosec loss reduc sale ramp-up expect ebitda break-even
ep break-even
figur solosec significantli ep neg lupin current
lupin like off-set
solosec loss
reduct share
significantli worri solosec ramp-up drug get traction
lupin like reduc market resourc drug reduc loss
charl martineau pm univers toronto lupin alreadi
market share
share
market new player
like enter low
otherwis lupin alreadi talk possibl buy anoth asset
women healthcar space could promot obstetricians/ gynecologist
field forc synergi achiev break-even solosec sooner
levothyroxin ramp-up start
stronger new capac
lupin alreadi achiev market share levothyroxin even without approv
rld approv expect month expect achiev
market share exit share market share
averag market share year levothyroxin market expect
competit levothyroxin market price eros may steep
new competit come limit capac interact compani
compani want commit high capac levothyroxin
volumin product price collaps econom attract
new capital-expenditure may use full advantag remain hormon product
figur levothyroxin upsid lupin fulli reflect
gener
effect lannett volum start transit amneal termin lannett distribut agreement jsp
albuterol inhal great opportun extent
upsid depend time approv
albuterol inhal market bn three brand ventolin proair
proventil total market size brand level bn prescript
market three
share
current written gener albuterol current captur authoris gener three
brand expect gener market share significantli ramp-up three
gener lupin cipla launch lupin manag
analyst meet mention price albuterol gener market come
meaning three authoris gener launch
lupin settlement date teva target action date
compani market share depend sequenc get approv
cipla assum market share lupin market share
assumpt clearer depend sequenc approv albuterol
gener remain low competit opportun follow-on competit limit
obtain first
date expect
share lupin
figur upsid albuterol inhal lupin
gener prescript
gener
lupin sale proair us mn
figur albuterol inhal volum share split authoris gener
market alreadi
charl martineau pm univers toronto factor
upsid cost
control guidanc
last four year due
wc increas
 increas
 moder
sale capital-expenditure
intens alreadi
sharp increas expect upgrad
lupin turn net debt past four year due weak acquisit gavi solosec
low higher wc intens margin contract due solosec price eros
metformin howev compani close debt free margin
bottom improv driven ramp-up levothyroxin solosec
albuterol inhal launch genbrel gspiriva lupin
alreadi moder capital-expenditure intens target price base
price-to-earnings ep ex amortis npv genbrel
gspiriva view spiriva upsid factor limit competit
larg opportun approv issu like gadvair cut
ep factor new tax rate guidanc higher
yet factor upsid cost control initi risk approv delay
genbrel albuterol inhal pend inspect indor dabhasa api
plant potenti escal oai flag mandideep gavi facil
disrupt generic-gener scale-up india
expect sharp increas next four year
lupin gener poor past four year except
due larg benefit price increas fortamet glumetza ramp-up due increas
work capit intens move sale sale due
channel consolid impact high gross net differ fortamet glumetza
figur sharp increas sale
capital-expenditure intens move sale lupin alreadi guid
moder sale capital-expenditure intens low lupin guid low
capital-expenditure well howev seem respit work capit intens
may continu high around sale
also impact larg loss solosec expect
full benefit albuterol inhal levothyroxin ramp-up
solosec close ebitda break-even well next leg improv
expect driven enbrel biosimilar ramp-up
europ spiriva gener launch lupin could close debt-fre
estim materialis current net debt bn adjust perindopril
charl martineau pm univers toronto figur expect signific pick-up profil lupin
solosec ramp
sharp wc
figur capit intens sale high sinc moder
low due acquisition-
high amortis depress profit
lupin made three larg acquisit gavi shionogi brand
portfolio japan solosec us bipresso in-licens japan
acquisit turn lupin net cash posit net debt figur also
intang becam one-third capit employ figur acquisit
work well far time result larg amortis impact
profit almost profit depress due amortis
acquisit none acquisit signific contributor earn
therefor target price calcul penalis lupin high amortis
acquisit alreadi account net debt
charl martineau pm univers toronto figur lupin turn net cash net debt due larg acquisit
acquir japan
figur high amortis depress profit
intang capit employ
amortis ep
ignor upsid
genbrel gspiriva
increas tp
upgrad outperform price
cautiou lupin market factor high sale
solosec ignor high product concentr us concern
address find market complet ignor upsid two good
product genbrel europ gspiriva inhal us expect sustain ramp-
next four year upgrad stock outperform
increas target price incorpor enbrel spiriva
upsid valu npv basi lupin alreadi approv genbrel japan
therefor good chanc approv eu need npv
approach enbrel upsid meaning start reflect onward lupin
filer spiriva gener time obtain approv expect launch
patent expiri cut ep factor
manag guidanc higher tax rate reduc
onward higher-than-expect spend rang
penalis compani high amortis profit acquisit
result high amortis meaning contributor longer
lupin guid substanti cost cut built upsid
potenti delay gener albuterol inhal ramp-up solosec stay
weak potenti cost cut act buffer
figur part cs target price
amort ep ad back credit suiss estim
risk outperform rate
delay us fda approv inhal enbrel biosimilar eu
sustain slow ramp solosec
two inhal file lupin signific ep contributor near term
medium-to-long term galbuterol contribut ep expect get
approv sinc first gener mdi approv us fda
risk unforeseen delay approv similarli ep larg contribut
spiriva second dpi gener approv us fda signific
delay first gener dpi advair approv fda requir gener
applic conduct addit test investig result delay similar
situat play could mean delay approv lupin well final
estim prone risk delay genbrel approv eu howev japan
approv provid comfort expect time approv eu
solosec ramp slower expect still less market share
nearli year sinc launch lupin incur annual market cost mn need
market share ebitda break-even continu sluggish impact
ramp-up assumpt solosec factor current sale estim
advers outcom forthcom us fda inspect indor
escal current oai flag
lupin face threat escal oai flag warn letter two facil
mandideep cephalosporin oral formul api somerset gavi oral
solid mandideep pend anda warn letter wont
ep impact somerset facil constitut us sale pend
anda howev risk warn letter low ep sinc
expect larg product approv facil
besid two facil await flag recent conclud inspect
aurangabad oral solid facil issu four observ
moreov two facil indor ii ophthalm oral solid goa oral solid
warn letter sinc re-inspect
receiv oai flag expect resolut
delay impact estim
delay approv
proair/spiriva
enbrel impact
risk oai flag
escal wl
mandideep
dabhasa api
plant
inspect near term
figur indor dabhasa api plant inspect near term year
inspect expect soon last inspect eir receiv
observ re-inspect lead oai flag
eir receiv
observ re-inspect lead oai flag
observ risk wl ep impact import alert ep us
sale pend anda dmf file
nai flag eir receiv
eir receiv
inspect expect soon last inspect vai flag observ
industri growth
upcom inspect two facil indor oral contracept
formul api dabhasa api advers outcom especi indor
impact estim
acceler growth generic-gener industri india
lupin brand gener busi india contribut ep recent
past renew push govern promot generic-gener drug
industri jan aushadhi scheme also wit entri two privat
player back larg manufactur estim industri take away
bp growth away brand gener market case higher-than-expect
shift volum toward generic-gener market lupin ep contribut india could
impact
compani mention price
